Tesofensine - Saniona

Drug Profile

Tesofensine - Saniona

Alternative Names: NS-2330; Tesofensine

Latest Information Update: 23 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeuroSearch
  • Developer Medix; Saniona
  • Class Antidementias; Antiparkinsonians; Chlorobenzenes; Heterocyclic bicyclo compounds; Neuroprotectants; Nootropics; Obesity therapies; Small molecules
  • Mechanism of Action Biogenic monoamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Obesity
  • Discontinued Alzheimer's disease; Parkinson's disease

Most Recent Events

  • 05 Apr 2018 Saniona plans a phase I trial to evaluate pharmacodynamic interaction between tesofensine and metoprolol on 24-hours mean heart rate (In volunteers) (PO) (NCT03488719)
  • 01 Feb 2018 Medix completes enrolment in its phase III trial for Obesity in Mexico
  • 01 Feb 2018 Saniona announces intention to submit NDA for Obesity in Mexico in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top